Cat. #153870
pROSA26-Puro-GFP CRISPR vector
Cat. #: 153870
Sub-type: Mammalian expression, CRISPR, shuttle
Availability: 3-5 days
Target: Gt(ROSA)26Sor; ROSA26
Bacterial Resistance: Ampicillin
Selectable Markers: Puromycin
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Dr Andrew Stephens ; Amy Wilson
Institute: Hudson Institute Of Medical Research
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: pROSA26-Puro-GFP CRISPR vector
- Research fields: Genetics
- Tool sub type: Mammalian expression, CRISPR, shuttle
- Backbone size without insert: 7866
- Bacterial resistance: Ampicillin
- Selectable markers: Puromycin
- Description: Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines and vectors for research use only. Ximbio can provide these CRISPR-Cas9 research tools to companies under a label-use only license.
- Additional notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license
- Recommended controls: Contains GFP for positive transfection/integration control
Target Details
- Target: Gt(ROSA)26Sor; ROSA26
Application Details
- Application notes: Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines and vectors for research use only. Ximbio can provide these CRISPR-Cas9 research tools to companies under a label-use only license.
